Molecular pathology of differentiated thyroid cancer

被引:3
作者
Greco, A. [1 ]
Borrello, M. G. [1 ]
Miranda, C. [1 ]
Degl'Innocenti, D. [1 ]
Pierotti, M. A. [2 ]
机构
[1] Natl Tumor Inst, IRCCS Fdn, Dept Expt Oncol & Mol Med, Mol Mech Unit, I-20133 Milan, Italy
[2] Natl Tumor Inst, IRCCS Fdn, Sci Directorate, I-20133 Milan, Italy
关键词
Thyroid carcinoma; RET; TRK; BRAF; Gene expression; GENE-EXPRESSION PROFILES; ACTIVATED-RECEPTOR-GAMMA; BRAF MUTATION; POST-CHERNOBYL; SIGNALING PATHWAY; PAX8-PPAR-GAMMA REARRANGEMENT; NEOPLASTIC TRANSFORMATION; NTRK1; REARRANGEMENTS; PAPILLARY CARCINOMAS; TARGETED EXPRESSION;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Thyroid cancer is the most common endocrine malignancy; it accounts for approximately 1% of all new case of cancer each year, and its incidence has increased significantly over the last few decades. The majority of thyroid tumors originate from follicular epithelial cells. Among them, papillary (PTC) and follicular carcinomas (FTC) represent the most common forms of differentiated thyroid cancer and account for approximately 80% and 15% of all cases, respectively. Specific genetic lesions are associated to each thyroid tumor histotype: BRAF mutations and RET/PTC and TRK oncogenes have been detected in PTC, whereas FTC is characterized by PAX8/PPAR gamma rearrangements and RAS mutations. In this review we summarize studies on the molecular biology of the differentiated thyroid tumors, with particular interest in the associated genetic lesions and their role in thyroid carcinogenesis. We also report recent findings on gene expression and miRNA profiles of PTC and FTC.
引用
收藏
页码:440 / 454
页数:15
相关论文
共 109 条
[1]   Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas [J].
Adeniran, AJ ;
Zhu, ZW ;
Gandhi, M ;
Steward, DL ;
Fidler, JP ;
Giordano, TJ ;
Biddinger, PW ;
Nikiforov, YE .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (02) :216-222
[2]   The GDNF family: Signalling, biological functions and therapeutic value [J].
Airaksinen, MS ;
Saarma, M .
NATURE REVIEWS NEUROSCIENCE, 2002, 3 (05) :383-394
[3]   RET and NTRK1 proto-oncogenes in human diseases [J].
Albert, L ;
Carniti, C ;
Miranda, C ;
Roccato, E ;
Pierotti, MA .
JOURNAL OF CELLULAR PHYSIOLOGY, 2003, 195 (02) :168-186
[4]   Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes [J].
Aldred, MA ;
Huang, Y ;
Liyanarachchi, S ;
Pellegata, NS ;
Gimm, O ;
Jhiang, S ;
Davuluri, RV ;
de La Chapelle, A ;
Eng, C .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (17) :3531-3539
[5]   Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas [J].
Aldred, MA ;
Morrison, C ;
Gimm, O ;
Hoang-Vu, C ;
Krause, U ;
Dralle, H ;
Jhiang, S ;
Eng, C .
ONCOGENE, 2003, 22 (22) :3412-3416
[6]   Pathways connecting inflammation and cancer [J].
Allavena, Paola ;
Garlanda, Cecilia ;
Borrello, Maria Grazia ;
Sica, Antonio ;
Mantovani, Alberto .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2008, 18 (01) :3-10
[7]  
[Anonymous], 2004, WHO CLASSIFICATION T
[8]   RET tyrosine kinase signaling in development and cancer [J].
Arighi, E ;
Borrello, MG ;
Sariola, H .
CYTOKINE & GROWTH FACTOR REVIEWS, 2005, 16 (4-5) :441-467
[9]   RET receptor signaling: Dysfunction in thyroid cancer and Hirschsprung's disease [J].
Asai, N ;
Jijiwa, M ;
Enomoto, A ;
Kawai, K ;
Maeda, K ;
Ichiahara, M ;
Murakumo, Y ;
Takahashi, M .
PATHOLOGY INTERNATIONAL, 2006, 56 (04) :164-172
[10]   BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment [J].
Begum, S ;
Rosenbaum, E ;
Henrique, R ;
Cohen, Y ;
Sidransky, D ;
Westra, WH .
MODERN PATHOLOGY, 2004, 17 (11) :1359-1363